News

Leerink Partners Raises Stock Target for Hims & Hers amidst Growth

Leerink Partners Raises Stock Target for Hims & Hers amidst Growth

Leerink Partners Upgrades Hims & Hers Stock Price Target

Recently, Leerink Partners, a well-known financial firm, revised its outlook for Hims & Hers Health, Inc. (NYSE: HIMS), lifting the stock price target to $26.00, up from a previous estimate of $21.00. This adjustment reflects the firm's confidence in the company's performance as it approaches the announcement of its third-quarter results, which are set to be shared soon.

Reasons Behind the Revised Price Target

The updated price target is driven by expectations of a strong revenue report, with projections reaching $398.8 million. This figure exceeds both the Visible Alpha consensus of $382.3 million and the company's own guidance of between $375 million and $380 million. A key factor contributing to this optimistic forecast is the anticipated growth in GLP-1 sales, which played a minor role in the previous quarter yet is now expected to significantly impact overall revenue.

Growth in GLP-1 Sales

Hims & Hers has integrated GLP-1 medications into its offerings, and this sales category is predicted to flourish, complementing the company's established product lines in weight management and other areas such as hair loss and sexual health. This transition underscores a strategic expansion that is likely to enhance revenue streams.

Adjusted EBITDA Forecast

The firm also adjusted its EBITDA forecast for Hims & Hers, projecting it at $39.0 million, just above the consensus estimate of $38.7 million and aligning with the management’s guidance range. This adjustment indicates the company’s positive operational efficiency and growth potential.

Market Performance Considerations

While the revenue outlook appears promising, Leerink does express some caution regarding the sustainability of GLP-1 sales as a continuous revenue source. They recognize Hims & Hers' potential for long-term growth but suggest that much of the growth might already be reflected in the current share price.

Recent Strategic Appointments

In a noteworthy operational development, Hims & Hers appointed Dr. Jessica Shepherd as the first Chief Medical Officer for its Hers division. This move is pivotal for enhancing the company’s commitment to personalized women's healthcare, further diversifying its market offerings.

Financial Performance Insights

On a financial note, Hims & Hers reported a remarkable revenue increase of 52% year-over-year during the second quarter of 2024, reaching $316 million. Furthermore, the adjusted EBITDA for this period stood at $39 million, showcasing a robust business model that aligns with market expectations.

Analyst Ratings and Market Reactions

Investment analysts, including those from BofA Securities, have reacted positively by raising their price targets for Hims & Hers, indicating solid market confidence. The company received a price target increase from $23 to $25 while maintaining a Buy rating, illustrating a favorable view of its stock performance.

Regulatory Developments Affecting Operations

The FDA has recently revisited its stance on Tirzepatide, a medication previously flagged for shortage. This reassessment could significantly influence Hims & Hers' operations, especially regarding their compounded GLP-1 products, which are now poised for potential market expansion.

InvestingPro Insights

Employing data from InvestingPro, Hims & Hers has demonstrated impressive growth, reporting a 50.15% increase in revenue year-over-year as of Q2 2024. This growth trajectory supports expectations for continued positive performance in upcoming quarters.

Profitability and Investor Confidence

Hims & Hers has achieved profitability over the past year, with analysts forecasting ongoing positive earnings in the near term. The company's strategic focus on expanding its revenue channels through GLP-1 sales and leveraging its market potential has garnered the trust of investors, reflected in a staggering 299.31% total return on stock over the past year.

Frequently Asked Questions

What is the new price target for Hims & Hers?

The new price target set by Leerink Partners for Hims & Hers is $26.00.

What factors contributed to the revised stock target?

The revised target is based on anticipated strong revenue growth, particularly from GLP-1 sales, and positive adjusted EBITDA forecasts.

Who has been appointed as the Chief Medical Officer?

Dr. Jessica Shepherd has been appointed as the inaugural Chief Medical Officer for the Hers division of Hims & Hers.

How much did Hims & Hers's revenue increase in Q2 2024?

The company reported a 52% year-over-year revenue increase in Q2 2024, reaching $316 million.

What is the significance of the FDA's reassessment of Tirzepatide?

The FDA's reassessment could impact Hims & Hers' operations and market strategy, particularly regarding their GLP-1 offerings.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Protein Now! Gains Clinician Attention, With Caveats

Updated Category News Views 91

A Small Bottle Has Drawn a Crowd Protein powder tubs have been cluttering kitchens for years; a 3.38-fluid-ounce shot is a cleaner answer to the same daily hassle. NutraBio Labs says more than 800 physicians, nurse practitioners, and physician associates had added PROTEIN NOW! to their individual FrontrowMD patient pages as of November 2026. That earned the product a...

Continue Reading
Branch's Fast 500 Rank Signals Payroll Platform Reach

Updated Category News Views 58

Six straight appearances on Deloitte's Fast 500 is not random confetti; it says Branch has kept finding customers while plenty of fintech outfits were busy shrinking their ambitions. The Tampa-based workforce-payments company landed at No. 146 in the 2026 ranking, which measures fiscal-year revenue growth from 2022 through 2025. That is a respectable showing in a list...

Continue Reading
SoCalGas Data Program Puts Metering Case Into Focus

Updated Category News Views 61

Buried beneath the usual utility-company polish is a pretty sensible idea: find waste before a customer gets walloped by a bill. SoCalGas says its Advanced Meter Analytics program has helped customers avoid an estimated $11 million in unnecessary natural-gas costs since 2019. That is not a number likely to move Sempra’s earnings by itself, and nobody should pretend...

Continue Reading
Perigon Builds Its Investment Bench for the Next Leg

Updated Category News Views 110

Perigon is rearranging the engine room before the next growth spurt gets noisy. The firm has named Christopher Broderick Director of Investments and Research, added two trading associates, and put another brick behind the broader operating structure Rafia Hasan has been assembling since taking on the chief operating officer role in August. That may sound like ordinary...

Continue Reading
Clear Aligner Results Depend on Discipline, Not Hype

Updated Category News Views 87

A Clear Tray Is Not a Magic Wand Transparent orthodontic trays sell a wonderfully tidy idea: straighten teeth without the metal-and-wire routine, take them out to eat, and carry on. Fair enough. But the useful message from Dr. Theresa Trapp is the part nobody should glide past: clear aligners are a treatment plan, not a cosmetic shortcut bought with good intentions....

Continue Reading
Cleveland Picks Golden Key for Citywide Leadership Training

Updated Category News Views 247

A Citywide Bet on Better Management Municipal management rarely grabs headlines until something breaks, which is precisely why Cleveland's decision to bring in Golden Key Group deserves a closer look. Announced November 20, 2026, the arrangement calls for GKG to design and deliver a citywide management training program through Cleveland's Department of Personnel and Human...

Continue Reading
Tampa General's Food Bet Earns a 2026 Innovation Award

Updated Category News Views 27

Hospital meals have long been the punchline nobody bothered to fix, which is why Tampa General Hospital's latest recognition deserves a closer look. The not-for-profit academic health system was named the 2026 Inno Pick by the Tampa Bay Business Journal for its Food as Medicine initiative, its fifth straight year landing among the publication's Inno Award honorees. Awards...

Continue Reading
Label-Free Detection Has a Solid, Narrow Growth Lane

Updated Category News Views 95

Biologics labs are turning into a far better hunting ground for analytical equipment than the old, broad-brush research story suggests. Label-free detection is not a giant market, and nobody should dress it up as one. But the projected move from $0.58 billion in 2026 to $0.85 billion by 2031 points to a useful 8.1% annual growth lane, driven by work researchers genuinely...

Continue Reading
San Bernardino Teamsters Back Their Historic Contract

Updated Category News Views 61

A 90% vote does not whisper; it rattles the filing cabinets. More than 12,000 San Bernardino County members of Teamsters Local 1932 have ratified a new labor agreement with over 90% approval, according to the union’s November 20 announcement. In a public-sector negotiation, that kind of margin matters because it tells management the workforce is not merely accepting a...

Continue Reading
Lara Kirchner's Surgical Leadership Earns Recognition

Updated Category News Views 64

Surgical care gets judged in the quiet moments nobody puts on a plaque: a sterile instrument ready when it must be, a handoff done cleanly, a team that does not let a rushed schedule turn into a bad outcome. That is why Lara L. Kirchner's recognition as a Pinnacle Professional of the Year deserves a more serious look than the usual congratulatory confetti. Kirchner is...

Continue Reading

Top 5 Most Recently Viewed Articles

Global Medical REIT Declares Significant 2024 Dividend Payments

Updated Category News Views 100

Global Medical REIT Inc. Announces 2024 Dividend Declares In an exciting update for shareholders, Global Medical REIT Inc. (NYSE: GMRE) has announced its board's decision to declare the 2024 fourth quarter common and preferred dividends. This revelation underscores the company's commitment to returning value to its investors, especially as it continues its growth...

Continue Reading
Predictive Dialer Software Market Growth and Insights for Businesses

Updated Category News Views 247

Rising Demand and Forecast for Predictive Dialer Software The predictive dialer software market is on an impressive trajectory, moving from a valuation of USD 2.6 billion to a staggering USD 45.1 billion in the coming years. This remarkable growth is primarily fueled by the increasing demand for telemarketing solutions and the rising number of automated contact centers...

Continue Reading
RWE and GE Vernova Collaborate for Energy Projects in the U.S.

Updated Category News Views 217

RWE Strengthens Partnership with GE Vernova for Sustainable Energy RWE has taken a significant step in advancing renewable energy in the U.S. by selecting GE Vernova as its trusted supplier for over 100 domestically produced wind turbines. This strategic decision will support two major energy projects, contributing 308 MW to the renewable energy grid. In doing so, RWE...

Continue Reading
Olin Corporation Reports Fourth Quarter Financial Highlights

Updated Category News Views 210

Olin Corporation's Financial Overview In a recent report, Olin Corporation (NYSE: OLN) disclosed its financial performance for the fourth quarter, showcasing a net income of $10.7 million, translating to $0.09 per diluted share. This figure reflects a decline compared to a net income of $52.9 million, or $0.43 per diluted share, seen in the corresponding quarter of the...

Continue Reading
Converge Technology Solutions Adjusts Dividend Payment Date

Updated Category News Views 214

Converge Technology Solutions Adjusts Dividend Payment Schedule Converge Technology Solutions Corp. (TSX: CTS) is set to enhance its dividend distribution process by moving the payment date forward due to holiday timings. Originally planned for December 28, 2024, shareholders can now expect to receive their dividend one day earlier, on December 27, 2024. This adjustment...

Continue Reading